Kazuhiro Shimomura

Aichi Cancer Center — Japan

Neuroscience · Life Sciences

27h-index7.4kcitations83works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Circadian rhythm and melatonin(18), Genetic Mapping and Diversity in Plants and Animals(10), Adipose Tissue and Metabolism(9), Sperm and Testicular Function(6), Genetics, Aging, and Longevity in Model Organisms(6)

Publications83 total

Montreal cognitive assessment domain-specific and clinical predictors of postoperative delirium in elderly gastrointestinal cancer patients
Surgery Today·2025
Subxiphoid robotic thymectomy for anterior mediastinal tumors located in cervical region
JTCVS Techniques·2025Open Access
Impact of renal function on non-hematologic toxicities in mCRC patients treated with TAS-102: a post-hoc analysis of the JASCC-CINV2001 study
Supportive Care in Cancer·2025
Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial
Diabetes Obesity and Metabolism·2024· 11 citedOpen Access
Author response for "Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial"
2024
1888-LB: Differential Effect of Imeglimin Compared with Metformin on Insulin and Incretin Secretion—A Randomized Controlled Trial
Diabetes·2024
The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review
Frontiers in Oncology·2024· 5 citedOpen Access
The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational study
Supportive Care in Cancer·2024· 1 cited
Public perceptions of physician-pharmaceutical industry relationships and trust in physicians
PLoS ONE·2023Open Access
Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)
British Journal of Cancer·2023· 13 citedOpen Access
Changes in Japanese physicians’ relationships with the pharmaceutical industry between 2008 and 2021: A national survey
PLoS ONE·2023· 2 citedOpen Access
Predictors of therapeutic efficacy of anamorelin in patients with gastric, pancreatic, and colorectal cancer.
Journal of Clinical Oncology·2023
Impact of Corticosteroids for IrAEs on the Clinical Outcome of Immunotherapy in Patients With NSCLC
Anticancer Research·2022· 6 cited
A missense mutation in <i>Kcnc3</i> causes hippocampal learning deficits in mice
Proceedings of the National Academy of Sciences·2022· 2 citedOpen Access
Effects of glucokinase activator, DS-7309, on embryo-fetal developmental toxicity in rats and rabbits
Regulatory Toxicology and Pharmacology·2022· 1 cited
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy
BMJ Open·2020· 6 citedOpen Access
0103 Novel Prebiotic Enhances Sleep-Wake Cycle and Memory Consolidation in 5xFAD Mice
SLEEP·2020Open Access
Genetics of Circadian Rhythms
Neurologic Clinics·2019· 34 citedOpen Access
A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer
The Oncologist·2018· 2 citedOpen Access
Investigation of the Exposure of Preparation Gloves to a Cyclophosphamide Preparation using Equashield&lt;sup&gt;®&lt;/sup&gt;
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)·2017· 1 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Joseph S. Takahashi(21), Martha Hotz Vitaterna(11), Gary A. Churchill(7), Fred W. Turek(7), Seung Hee Yoo(6), Michael Menaker(5), Shin Yamazaki(4), Phillip L. Lowrey(4), Ethan D. Buhr(4), Andrew R. Whiteley(4), Nasim Ahmadiyeh(4), Eva E. Redei(4), Lawrence H. Pinto(4), Toshiki Matsuoka(4), Leah C. Solberg(3), Amber E. Baum(3), Vivek Kumar(3), Tim Wiltshire(3), Kazunari Nohara(3), Zheng Chen(3)